跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RR-1
首页
药物
RR-1
RR-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CYCLIC AMIDES, ACTEAMIDES AND UREAS USEFUL AS POTASSIUM CHANNEL OPENERS
EP 3366683 A1
申请人: ACOUSIA THERAPEUTICS GMBH
优先权: 2017
CN
EP
US
6 件公开
EPISULFIDE COMPOSITION, POLYMERIZABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, AND LENS
US 20260226236 A1
申请人: MITSUI CHEMICALS INC
优先权: 2023
CN
EP
US
WO
4 件公开
EP 4656634 A1
申请人: MITSUI CHEMICALS INC
优先权: 2023
CN
EP
WO
3 件公开
METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
EP 4304657 A4
申请人: PEPGEN INC
优先权: 2021
EP
US
WO
3 件公开
PHARMACEUTICAL COMPOSITION
US 2013129738 A1
申请人: SHIBASAKI FUTOSHI
优先权: 2009
CN
US
2 件公开
Esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
US 6894076 B2
申请人: VITA INVEST SA
优先权: 1999
US
2 件公开
Macrocylic inhibitors of hepatitis C virus
US 7659245 B2
申请人: TIBOTEC PHARM LTD
优先权: 2005
US
2 件公开
Cyclopropylindole derivatives
US 6909006 B1
申请人: SPIROGEN LTD
优先权: 1999
US
Efficient carbamate synthesis
US 6399808 B1
申请人: UNIV SOUTH FLORIDA
优先权: 2000
US
Use of an organometallic compound for protecting and/or strengthening keratinous materials, and method of treatment
EP 1172079 A1
申请人: OREAL
优先权: 2000
EP
Fab I inhibitors
US 6503903 B1
申请人: SMITHKLINE BEECHAM CORP
优先权: 2001
US
第 1 / 7 页
上一页
下一页
药物
反馈